Daily Archives: November 7, 2020

Market Overview:

Global Atopic Eczema Treatment Market is anticipated to grow at a robust rate during the forecast period on account of the rising geriatric population across the world and the rising number of individuals diagnosed with chronic diseases such as cardiac disorders, diabetes, and various respiratory disorders. Growth in the region is attributed to various other factors, such as increasing awareness among the population regarding their health and ever-advancing technologies that are changing the face of hospitals and medical devices.

The Global Atopic Eczema Treatment Market Research Report is a valuable source of insightful data for business strategists. It provides the Atopic Eczema Treatment industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Atopic Eczema Treatment market study provides comprehensive data which enhances the understanding, scope and application of this report.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Get Sample Copy Page @ https://www.globalintelligenceandinsights.com/request-sample-1001209

Companies Profiled in this report includes:

Sanofi SA

Allergan Plc.

Novartis International AG

Bristol-Myers Squibb

Bayer AG

Meda Pharmaceuticals

Anacor Pharmaceutical Inc.

Pfizer

Astellas Pharma Inc.

Regeneron Pharmaceuticals

The report firstly introduced the Atopic Eczema Treatment Market basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; processes; cost structures and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, capacity utilization, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

This report provides comprehensive analysis of

Key market segments and sub-segments

Evolving market trends and dynamics

Changing supply and demand scenarios

Quantifying market opportunities through market sizing and market forecasting

Tracking current trends/opportunities/challenges

Competitive insights

Opportunity mapping in terms of technological breakthroughs

Global Atopic Eczema Treatment Market: Regional Segment Analysis:

North America

Europe

China

Japan

Southeast Asia

India

Global Atopic Eczema Treatment Market: Product Segment Analysis:

Type 1

Type 2

Type 3

Global Atopic Eczema Treatment Market: Application Segment Analysis:

Application 1

Application 2

Application 3

Reasons for Buying this Report:

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Get Up to 20% Discount on this Premium Report @ https://www.globalintelligenceandinsights.com/request-sample-1001209

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Global Intelligence and Insights is one of the top resellers of market research reports, including market intelligence, data solutions, competitive positioning, and custom intelligence to an array of organizations globally. Our customer portfolio includes business organizations from fortune 500 companies, SMEs, start-ups, financial technology start-ups, and venture capitalists. We have an exhaustive database of market research reports provided by more than 20 leading publishers across different industry verticals.

We provide tailored solutions that can be utilized to solve business challenges and problems faced by organizations in different regions. Additionally, our bouquet of solutions assists enterprises in strategic planning and staying ahead of the competition while getting access to extensive market forecast and trend mapping over the future course of time. In addition to the market forecast and other vital components of the market analysis, our reports include in-depth micro-macro analysis of the market, which aids the customers in analyzing the market ecosystem, thus assisting in the existing and new players in the development of strategic plans.

Contact Us:

Global Intelligence Insights

Bruno Abraham

US: +1-571-577-4575

202 Church Street SE,

Suite 301, Leesburg,

VA 20175

[emailprotected]

Originally posted here:
Atopic Eczema Treatment Market 2025 Insights by Size, Growth, Trends, Share, Competitive Analysis By Emerging Technology and Advancement - PRnews...

Take a look at some of the biggest movers in the premarket:

General Motors (GM) The automaker reported quarterly earnings of $2.83 per share, beating the consensus estimate of $1.38 a share, helped by strong demand for trucks and SUVs. Revenue was essentially in line with Street forecasts. The shares rose 6.7% in premarket trading as of 7:44 a.m. ET.

Cigna (CI) The insurance company came in 17 cents a share above estimates, with quarterly earnings of $4.41 per share. Revenue also came in above Wall Street forecasts, helped by higher sales in Cigna's health services unit.

Merck (MRK) Merck is buying privately held drugmaker VelosBio for $2.75 billion in cash, in a move designed to boost its oncology treatment pipeline.

Regeneron (REGN) Regeneron earned $8.36 per share for its latest quarter, beating the $7.14 a share consensus estimate. The drugmaker's revenue also came in above forecasts, boosted by improved sales of drugs like eye treatment Eylea and eczema drug Dupixent.

Capri Holdings (CPRI) The company behind luxury brands like Michael Kors reported quarterly earnings of 90 cents per share, well above the 4 cents a share consensus estimate. Revenue beat forecasts as well. Strong demand in China and a surge in online sales helped drive Capri's better-than-expected quarter. The shares jumped 12% in premarket trading as of 7:44 a.m. ET.

Canada Goose (GOOS) The outerwear maker earned 10 cents per share (Canadian) for its second quarter, compared to the consensus estimate of a 3 cents per share loss. Revenue was also above forecasts as online sales jumped and as the company saw strong demand in China for its parkas.

New York Times (NYT) The newspaper publisher doubled estimates with quarterly earnings of 22 cents per share. Revenue was also above estimates, driven by an increase in digital subscriptions.

Hanesbrands (HBI) The apparel maker beat estimates by 3 cents a share, with quarterly earnings of 42 cents per share. Revenue also exceeded forecasts. Hanesbrands saw better sales for its Champion brand, and also reported an overall boost in digital sales. The shares jumped 14% in premarket trading as of 7:44 a.m. ET.

Barrick Gold (GOLD) The mining company increased its dividend by 12.5% after reporting quarterly profit that nearly tripled from a year earlier. Barrick benefited from a surge in gold prices during the quarter. The shares added 2% in premarket trading as of 7:44 a.m. ET.

Becton Dickinson (BDX) The medical products maker beat estimates by 27 cents a share, with quarterly profit of $2.79 per share. Revenue topped estimates as well. Results were boosted by a jump in sales of Covid-19 -related products like testing kits.

Qualcomm (QCOM) Qualcomm reported quarterly earnings of $1.45 per share, beating the consensus estimate of $1.17 a share. Revenue also came in above forecasts and the chipmaker gave an upbeat current-quarter forecast as Apple (AAPL) and other handset makers ramp up production of 5G phones that utilize Qualcomm chips. The shares surged 14% in premarket trading as of 7:44 a.m. ET.

Apple (AAPL) Apple is facing a shortage of power consumption chips for its new iPhone 12 line, according to people with knowledge of the matter who spoke to Bloomberg. Apple declined to comment when contacted by CNBC.

Amazon.com (AMZN) Amazon CEO Jeff Bezos sold more than $3 billion in Amazon shares in August, according to a Securities and Exchange Commission filing. Bezos has sold about $10.2 billion in shares this year, but still owns more than 53 million shares worth about $170 billion.

AstraZeneca (AZN) The drugmaker said it expected to see data from its late-stage trial involving its Covid-19 vaccine candidate later this year. AstraZeneca also reported better-than-expected quarterly sales, although profit fell short of analysts' forecasts.

Aphria (APHA) Aphria will buy craft brewer SweetWater Brewing Co. for $300 million, as the Canadian cannabis producer expands in the U.S. and enters the alcoholic beverages market.

Apache (APA) Apache reported a smaller-than-expected loss for its latest quarter, with the oil producer also accelerating cost cuts. Apache also said capital spending this year would come in at the low end of its prior forecast.

Expedia (EXPE) Expedia reported a quarterly loss of 22 cents per share, compared to forecasts of a 79 cents per share loss. The travel services company's revenue came in above estimates, even as travel demand continues to be impacted by the pandemic. The shares rose 4% in premarket trading as of 7:44 a.m. ET.

Zynga (ZNGA) Zynga lost 11 cents per share for its latest quarter, 2 cents a share smaller than analysts had anticipated. The mobile game maker's revenue above forecasts. Active user numbers rose to record levels, with its games like "Words With Friends" gaining popularity amid the pandemic. The shares lost 5% in premarket trading as of 7:44 a.m. ET.

Match Group (MTCH) Match reported better-than-expected earnings and revenue for the third quarter, as the pandemic helped boost the popularity of its dating services. Tinder, which is Match Group's most widely-used app, saw subscriber numbers jump 16% from a year earlier. The shares rose 4% in premarket trading as of 7:44 a.m. ET.

Original post:
Stocks making the biggest moves in the premarket: General Motors, Cigna, Merck, Regeneron & more - CNBC

Sunday, November 01, 2020

'); } else { $(".fotorama-caption").addClass("remove_caption"); } }) .fotorama();

MOTHERS can pass allergies to offspring while they are developing in the womb, researchers from the Agency for Science, Technology and Research (A*STAR), KK Women's and Children's Hospital (KKH) and Duke-NUS Medical School in Singapore reported last week in the journal Science .

The study, which employed an animal model conducted according to the National Advisory Committee for Laboratory Animal Research (NACLAR) guidelines, shows that the key antibody responsible for triggering allergic reactions, immunoglobulin E (IgE), can cross the placenta and enter the foetus. When inside the foetus, the antibody binds to foetal mast cells, a type of immune cell that releases chemicals that trigger allergic reactions, from runny noses to asthma.

After birth, newborn mice develop allergic reactions to the same type of allergen as their mothers at the time of first exposure unlike adult mice, which require two exposures. Studies in the laboratory also showed that maternal IgE can bind to human foetal mast cells, indicating they might cross the placenta in humans in a similar way.

Dr Florent Ginhoux, senior principal investigator at A*STAR's Singapore Immunology Network (SIgN) and a senior co-author of the study, said: There is currently a significant lack of knowledge on mast cells that are present early on in the developing foetus. Here, we discovered that foetal mast cells phenotypically mature through the course of pregnancy, and can be sensitised by IgE of maternal origin that cross the placental barrier. The study suggests that a highly allergic pregnant mother may potentially transfer her IgE to her baby that consequently develop allergic reactions when exposed to the first time to the allergen.

Allergies begin very early in life, said Associate Professor Ashley St John, an immunologist at Duke-NUS' Emerging Infectious Diseases Programme and a senior co-author of the study. Infants experience allergic responses closely linked with the mother's allergic response in ways that cannot only be explained by genetics. This work emphasises one way that allergic responses can pass from the mother to the developing foetus, and shows how allergies can then persist after birth.

As part of the study, following NACLAR guidelines, researchers exposed mice to ragweed pollen, a common allergen, prior to pregnancy. Mice that developed a sensitivity to the pollen had offspring that also showed an allergic reaction to ragweed. The sensitivity is allergen-specific; the offspring did not react to dust mites, another common allergen.

Notably, the transfer of sensitivity appears to fade with time. The newborn mice had allergic reactions when tested at four weeks, but less or none at six weeks.

The experimental studies were backed up with cellular tests and imaging, which showed maternal IgE bound to foetal mast cells, triggering the mast cells to release chemicals in reaction to an allergen, a process called degranulation.

This study further showed that the IgE transfer across the placenta requires the help of another protein, FcRN. Mice with FcRN knocked out lacked maternal IgE attached to their mast cells, and did not develop allergies after birth.

The study findings potentially open new intervention strategies to limit such transfer to minimise the occurrence of neonatal allergies. Currently, between 10 to 30 per cent of the world's population are affected by allergies. This number is set to continue rising and a solution preventing allergies being passed from mother to child could potentially bring those numbers down over time.

Our research has really exciting findings that may explain the high incidence of early onset atopic dermatitis (eczema) in children of mothers with clinically proven eczema, which parallel findings in our local birth cohort findings, said Professor Jerry Chan, senior consultant, Department of Reproductive Medicine at KKH, senior National Medical Research Council clinician scientist, and vice-chair of research with the Obstetrics and Gynaecology Academic Clinical Programme at the SingHealth Duke-NUS Academic Medical Centre. From a clinical point of view, developing a further understanding in placental transfer of IgE, and the mechanism of foetal mast cell activation would be key to developing strategies to reduce the chance of eczema or other allergies from being transferred from mother to baby.

The authors next aim to better understand the mechanism of IgE transfer through the placenta, how IgE binding to mast cells in foetal skin modulate their functions and how it could affect skin physiology after birth.

ScienceDaily

Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at http://bit.ly/epaper-login

See the original post:
Mothers pass on allergies to offspring - Jamaica Observer

Ex-Kiss FM presenter Adelle Onyango. PHOTO | COURTESY

Former Kiss fm radio presenter Adelle Onyango has revealed how she hated her body for years after she was raped.

In an Instagram post, Adelle, who was in a bikini, said she hated her body because it reminded her of her scars and her rape ordeal.

In 2008, Adelle was raped by a stranger while she was leaving a house party to hit a club in Westlands.

I am so proud of the intentional work Ive done to get to a point of loving my body. For many years I hated it. I dont know, I think at the time parts of it reminded me of getting rapedthe scars. Then came eczema with its own scars as if to mock me, she wrote.

Adelle further indicated that since the rape ordeal and the eczema, a swimming suit became a no for her for years.

Getting into a swimsuit was justa no-no! Which sucked because Ive been a swimmer all my life and I loved it! So I hid it tights, long sleeves, double sleeves, dont swim, the works! I hardly looked at it. Didnt give it the healthy things it needed. For years.yikes!

Over the years however, she disclosed, she had learnt to love her body even though it has been a long journey of healing and acceptance.

But right now I respect and honor the divinity in this body. Its carried me through battlefields and continues to do so to date. Heres to intentional healing. Its hard. It takes time. Im not all the way there. But it really is the gateway to freedom! she concluded.

See more here:
Adelle: I hated my body, it reminded me of my rape ordeal - Nairobi News